LLY
Snapshot
mcap $1.0T · fwd P/E 24.5 · P/S 12.9 · rev +48% y/y · margin 34% · short 0.7% of float · beta 0.5 · earnings in 58d · 77% of 52w range
Active theses holding LLY
Recent news
Eli Lilly Stock 30% Undervalued Despite FDA Approval, DCF Shows
Eli Lilly stock appears roughly 30% undervalued per a Discounted Cash Flow (DCF) model, which estimates an intrinsic value of about $1,688 per share against a recent lower share price. The DCF analysis projects growing f
Aug 31, 2026
OmniAb Partners with Eli Lilly for Ion Channel Therapeutics
On August 17, OmniAb announced a global collaboration with Eli Lilly to discover and develop novel ion channel therapeutics. The deal grants Lilly exclusive global commercialization rights in exchange for an upfront paym
Aug 28, 2026
Eli Lilly adds Alzheimer's deal, obesity cost data support Zepbound
Eli Lilly has entered a research collaboration with BioArctic to use its BrainTransporter technology for a potential Alzheimer's treatment, expanding Lilly's neurodegenerative disease work beyond its diabetes and obesity
Aug 26, 2026
LLY vs ABBV: Which Drugmaker Has Stronger Growth Prospects?
Eli Lilly and AbbVie are leading U.S. drugmakers with strong portfolios and pipelines, but Lilly's growth prospects are currently driven by its cardiometabolic franchise. Lilly's Mounjaro and Zepbound generated $27.6 bil
Aug 25, 2026
Eli Lilly Targets $100 Billion Revenue with 18% Upside
Eli Lilly, trading at $1,255.40, targets $100 billion in revenue by fiscal 2026, with management guiding $85–$87 billion. The stock has a 24/7 Wall St. price target of $1,480.01, implying 17.89% upside, supported by a 90
Aug 24, 2026
Bristol-Myers Squibb and Eli Lilly Take Divergent Paths
On August 10, Bristol-Myers Squibb announced a $2.3 billion investment in a new 600,000-square-foot Houston plant, part of a $40 billion U.S. commitment expected to create 500 skilled and 2,000 construction jobs from 202
Aug 21, 2026
CVS slashes weight-loss consultation fee to $29, targets GLP-1 market
On August 5, CVS Health cut the cash price of its MinuteClinic online weight-loss consultation to $29, the lowest in the retail telehealth market for a GLP-1 evaluation, with no membership or monthly fee. The move aims t
Aug 08, 2026
Eli Lilly gains FDA Breakthrough nod for olomorasib in pancreatic cancer
Eli Lilly's KRAS G12C inhibitor olomorasib received FDA Breakthrough Therapy designation for advanced pancreatic cancer with a KRAS G12C mutation, adding to a prior breakthrough tag in lung cancer. Lilly also entered a c
Aug 08, 2026
Think you know where LLY goes next? Post the thesis and the AI scores it against live news.
Sign up free